Sable Offshore Faces Legal Heat After Pipeline Setback, But Eyes Q3 Restart
That came after the California State Land Commission flagged issues with Sable's public statements and a court ordered a preliminary injunction against its pipeline work, events that triggered a ~15% stock drop. This legal spotlight isn't a kill switch, but it puts Sable under pressure and may delay its operational ramp-ups; the kind of risk-reward trigger hedge funds actively scan upstream.
Oil workers working on a large oil drilling rig in the Gulf Coast region.
Despite the scrutiny, Sable continues to fortify its financial footing. That mix of regulatory overhang plus rising momentum makes SOC a classic turnaround play for funds focused on upstream catalysts. If the investigation clears and pipeline work completes, the share upside could be sharp.
Sable Offshore is a pure-play offshore drilling developer centered on its Santa Ynez Unit off California. The company is preparing for a full operational restart by Q3, contingent on legal and regulatory resolution.
While we acknowledge the potential of SOC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: and .
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA
We recently compiled a list of Alnylam Pharmaceuticals, Inc. stands eighth on our list and recently got approval for AMVUTTRA. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, with four FDA-approved drugs for rare genetic diseases. Recently, the company has made significant strides in treating transthyretin amyloidosis (ATTR), a progressive disease affecting the heart and nerves. In March 2025, the FDA approved AMVUTTRA (vutrisiran) to reduce cardiovascular death and hospitalizations in ATTR-CM patients, based on strong results from the HELIOS-B Phase 3 trial. The drug also received approval from the European Commission in June 2025. Long-term data (up to 42 months) continues to support its effectiveness in improving heart function and quality of life. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), considered one of the most undervalued stocks in the biotech sector, is advancing nucresiran (ALN-TTRsc04), a next-gen RNAi treatment for ATTR. Interim Phase 1 results show sustained TTR protein reduction (over 90% within 15 days), with potential for once- or twice-yearly dosing. The drug enters Phase 3 trials in 2025 through the TRITON-CM program, aiming for longer-lasting, more convenient treatment options. A close-up of a staff member counting pills in a pharmaceutical warehouse. Beyond ATTR, the business is expanding its pipeline with nine new investigational therapies by the end of 2025, including treatments for Huntington's disease, bleeding disorders, and type 2 diabetes. The company also initiated a landmark Phase 1 trial for ALN-HTT02 in Huntington's, marking its entry into neurotherapeutics. Platform upgrades are targeting improved delivery to organs like the brain, heart, and kidneys, enhancing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s ability to address both rare and common diseases. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Molina Healthcare, Inc. (MOH) Wins Major Medicaid Contracts in 4 States
We recently compiled a list of Molina Healthcare, Inc. (NYSE:MOH) is a leading managed care provider offering government-sponsored healthcare programs like Medicaid and Medicare to low-income individuals and families across the U.S. Headquartered in Long Beach, California, Molina operates health plans in multiple states and serves millions through Medicaid, Medicare, and dual-eligible Special Needs Plans (D-SNPs). The company recently secured major Medicaid contract wins and renewals in states like Georgia, Idaho, Massachusetts, and Ohio, which will contribute to revenue growth and expand access to care. Molina Healthcare, Inc. (NYSE:MOH) also acquired ConnectiCare Holding Co., adding 140,000 members, and previously took over Bright Health's assets in California. A key strategic focus is the dual-eligible population, those covered by both Medicaid and Medicare, due to their complex needs and potential for integrated, high-quality care. Molina is developing blended service models and adjusting policy and reimbursement structures to address this growing segment. A healthcare professional wearing a health communications device discussing patient data with a colleague. Molina Healthcare, Inc. (NYSE:MOH) remains active in community engagement, such as maternal health initiatives in Texas. It's also prioritizing behavioral health and chronic condition management through updated protocols and external partnerships. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
UnitedHealth Group Incorporated (UNH) Expands Rural Care with $7M in Maternal Health Grants
We recently compiled a list of It is the largest U.S. health insurer, operating through its insurance arm (UnitedHealthcare) and health services division (Optum). It serves over 50 million people and continues to focus on transforming care delivery through value-based care, integrated services, and investments in social determinants of health. In May 2025, Stephen J. Hemsley returned as CEO, replacing Andrew Witty. The leadership shift comes amid uncertainty, with the company withdrawing its 2025 financial outlook but reaffirming its long-term goals of improving healthcare access, quality, and affordability. UNH is expanding care access, particularly for underserved and rural populations. Through the UnitedHealth Foundation, the company partnered with Cherokee Health Systems to improve rural prescription delivery. It also committed $7 million in grants to maternal and infant health, and its affordable housing-linked health investments reached $1.2 billion. A major project in Minneapolis will include 83 housing units and a new health center expected to serve 3,000 additional patients annually. For 2025, UnitedHealth Group Incorporated (NYSE:UNH) introduced 140 new Medicare Advantage plans, expanding support for chronically ill and dual-eligible populations. The Chronic Special Needs Plans (C-SNPs) will significantly increase coverage. Optum plans to serve 650,000 more patients under value-based care, leveraging AI tools to enhance coordination and preventive care. 15 States with the Best Healthcare in the US Optum is deepening its home-care services following its 2023 acquisition of LHC Group and now aims to acquire Amedisys. If approved, the deal would give Optum major market share in several states. However, the Department of Justice is reviewing the merger for potential antitrust violations. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
